Evaluation of Cognitive Functions in Schizophrenic Patients with the Montreal Cognitive Assessment Scale and Mini-Mental State Examination

Year 2022, Volume: 5 Issue: 3, 553 - 557, 01.09.2022

Serkan Zincir

https://doi.org/10.19127/bshealthscience.1110688

Abstract

Schizophrenia is a complex neurodevelopmental disorder. Cognitive deficit is the central feature of the neurodevelopmental disorders. Cognitive impairment is related to social, functional, and clinical symptoms. The aim of this study was to investigate the clinical usability of the Montreal Cognitive Assessment (MoCA) as a screening instrument for cognitive impairment in schizophrenic patients alone, and in correlation with the Mini-Mental State Examination (MMSE). This clinical study included 31 patients diagnosed with schizophrenia. Patients were selected from Psychiatry Clinic. For the assessment of cognitive impairment, we used Montreal Cognitive Assessment Scale (MoCA) and Mini-Mental State Examination (MMSE). Of the total number of patients (n=31), 6/31 (19.4 %) were males and 25/31 (80.6 %) were females; the mean duration of the disorder was 23.5 years (SD=6.69). Seventeen patients (54.8%) of those who were on MMSE scale had a score greater or equal to 24 (normal range) and the MoCA scale had a normal score (>21), while 11 (35.5%) patients reported moderate to severe cognitive impairment. Analysis of the correlation coefficient between the total score of MoCA and the MMSE scale indicates a statistically significant positive correlation with Spearman rho=0.81 and P<0.001. Our findings provide preliminary evidence that the MoCA scale performs well in screening mild and moderate cognitive impairments of schizophrenia patients in outpatient clinics and is more sensitive than MMSE.

Keywords

Schizophrenia, Cognitive Impairment, MoCA, MMSE

References

• APA. 1994. American psychiatric association: Diagnostic and statistical manual of mental disorders, (DSM-IV). American Psychiatric Association, Washington DC, USA, 4th ed, pp 750.
• Fisekovic S, Memic A, Pasalic A. 2012. Correlation between MoCA and MMSE for the assessment of cognition in Schizophrenia. Acta Inform Med, 20: 186-189.
• Green MF, Kern RS, Braff DL, Mintz J. 2000. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the ‘‘right stuff’’? Schizophrenia Bull, 26: 119-136.
• Gungen C, Ertan T, Eker E, Yaflar R, Engin F. 2002 Reliability and validity of the standardized Mini Mental State Examination (MMSE) in the diagnosis of mild dementia in Turkish population. Türk Psikiyat Derg, 13: 273–281.
• Kay SR, Flszbein A, Opfer LA. 1986 The positive and negative syndrome scale (PANSS). Rat Man Soc Behav Sci Doc. 17: 28-9.
• Keefe RS, Fenton WS. 2007 How should DSM-V criteria for schizophrenia include cognitive impairment? Schizophr Bull, 33: 912–920.
• Kostakoğlu E, Batur S, Tiryaki A, Göğüş A. 1999 Reliability and validity of Positive and Negative Syndrome Scale (PANSS-TR). Türk Psikiyat Derg, 14: 23-32.
• Kurtz MM, Seltzer JC, Fujimoto M, Shagan DS, Wexler BE. 2009. Predictors of change in life skills in schizophrenia after cognitive remediation. Schizophr Res, 07: 267-74.
• Lencz T, Smith CW, McLaughlin D, Auther A, Nakayama E, Hovey L. 2006 Generalized and specific neurocognitive deficits in prodromal schizophrenia. Biol Psychiatry, 59: 863-871.
• Lewis R. 2004. Should cognitive deficit a diagnostic criterion for schizophrenia? J Psychiatry Neurosci, 29:102–113.
• Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I. 2005 The Montreal Assessment (MoCA): a brief screening tool for mild cognitive impairment. J Am Geriatr Soc, 53: 695-696.
• O’Carrol R. 2000. Cognitive impairment in schizophrenia. Adv Psychiatr Treat, 6: 161-168.
• Ozdilek B, Kenangil G. 2013 Reliability and validity of the Turkish version of the MoCA scale in Parkinson’s disease. In: Proceedings of the 17th International Congress of Parkinson’s Disease and Movement Disorders, June 16-20, Sydney, Australia, pp. 511.
• Preda A, Adami A, Kemp AS, Nguyen, D. 2011. MoCA: A screening instrument for the assessment of cognition in schizophrenia. In: Proceedings of the 13th International Congress on Schizophrenia Research (ICOSR), April 2-6, Colorado Springs, Colorado, USA, 37: 225-226.
• Selekler K, Cangoz B, Uluc S. 2010. Power of discrimination of Montreal cognitive assessment (MoCA) scale in Turkish patients with mild cognitive impairment and Alzheimer’s disease. Turk J Geriatr, 13:166-171.
• Smith T, Gildeh N, Holmes C. 2007. The Montreal cognitive assessment: validity and utility in a memory clinic setting. Can J Psychiat, 52: 329-332.
• Soygür H, Alptekin K, Atbaşoğlu C, Herken H. 2007. Schizophrenia and the other psychotic disorders. Türk Psikiyat Derg, 2: 236-249.